Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study

Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.

Authors

Affiliations

¹ Newcastle upon Tyne, UK.
² Hull, UK.
³ London, UK.
⁴ Wolverhampton, UK.
⁵ Liverpool, UK.
⁶ Birmingham, UK.
⁷ Torquay, UK.
⁸ Exeter, UK.

Abstract

LINKED CONTENT

This article is linked to Taxonera et al paper. To view this article, visit https://doi.org/10.1111/apt.15804

Publication types

Letter
Comment

MeSH terms

COVID-19*
Cohort Studies
Humans
Inflammatory Bowel Diseases* / complications
Inflammatory Bowel Diseases* / drug therapy
Inflammatory Bowel Diseases* / epidemiology
SARS-CoV-2
United Kingdom / epidemiology